Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7366 to 7380 of 7687 results

  1. Violence: short-term management for over 16s in psychiatic and emergency departments (CG25)

    This guideline has been updated and replaced by NICE guideline NG10.

    Clinical guideline
    Published
    23 February 2005

  2. Post-traumatic stress disorder: management (CG26)

    This guidance has been updated and replaced by NICE guideline NG116.

    Clinical guideline
    Published
    23 March 2005

  3. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development [GID-TA11443] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  7. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  9. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Technology appraisal guidance
    Published
    12 June 2024

  11. GaitSmart assessment and vGym personalised exercise rehabilitation programme for people with gait and mobility issues (MIB283)

    This medtech innovation briefing (MIB) has been replaced by NICE medical technologies guidance on GaitSmart rehabilitation exercise programme for gait and mobility issues.

    Medtech innovation briefing
    Published
    1 February 2022

  12. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE medical technologies guidance 76. 

    Medtech innovation briefing
    Published
    1 February 2022

  13. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This guidance has been updated and replaced by NICE diagnostics guidance 60.

    Medtech innovation briefing
    Published
    7 March 2023

  14. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Technology appraisal guidance
    Published
    15 May 2019

  15. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development [GID-TA11146] Expected publication date: TBC

    Technology appraisal guidance
    In development